Artrya Limited

The Business

Artrya develops AI software that analyses coronary CT angiography (CCTA) scans, a type of cardiac imaging that produces detailed pictures of coronary arteries. The Salix platform has two FDA-cleared modules: one identifying anatomical blockages, one characterising plaque composition and distinguishing stable from vulnerable deposits. A third module measuring blood flow restriction (fractional flow reserve) is pending FDA clearance. The company charges U.S. hospitals per scan at rates anchored to a US$950 CPT reimbursement code, the billing code that determines what Medicare and private insurers pay. Revenue is effectively zero: approximately A$0.1M annualised from three foundation customers, all signed before the formal commercial launch. HeartFlow dominates the market with roughly 1,000 installed sites. Cleerly, a well-funded private competitor, holds its own plaque clearance and carries an implied valuation near US$1 billion.

Recent Performance

The stock has surged from under A$1.00 to A$4.58, driven by FDA clearances, a successful A$80M capital raise, and ASX index inclusion generating passive fund demand. None of this price movement reflects commercial traction. Quarterly customer receipts in Q3 FY26 totalled A$46,000. No new customers were announced. The divergence between share price momentum and business momentum is the defining feature of this investment case.

Outlook

The near-term revenue path depends on three existing customers going fully live and gradual additions of new hospital systems. Even in that scenario, EBITDA remains deeply negative, with operating costs exceeding gross profit by a wide multiple throughout the foreseeable forecast period. Gross margins should expand materially as the software delivery model scales, but margin expansion is immaterial when the cost base dwarfs revenue by a factor of seven or more. Reaching breakeven requires in excess of 65 U.S. customers, a figure that demands sustained annual wins of five to eight hospital systems against an incumbent with roughly 300 times the current installed base.

Key Risks

Adoption failure is the primary risk. Zero new customers were signed during Q3 FY26 despite an active commercial team, and hospital procurement cycles typically run 12-18 months, meaning the pipeline is not yet generating revenue even if conversations are progressing. Competitive displacement is the second material risk: if HeartFlow adds a plaque characterisation module (a single FDA filing away), the core differentiator underpinning Artrya's commercial pitch is substantially weakened. Cash exhaustion is the structural risk underpinning both: at the current quarterly burn rate, the A$76.6M cash balance depletes by year four, requiring a capital raise that would likely prove dilutive to existing shareholders at a depressed price.

What to Watch

The SAPPHIRE clinical study has enrolled six major U.S. health systems, including Ascension and Mass General Brigham. Site conversions from clinical use to commercial contracts are the single most important observable event in the investment thesis. If a meaningful number convert, the adoption trajectory shifts and the probability distribution across outcomes changes materially. If sites stall or drop out, the bear case is reinforced.

• H2 CY2026 to H1 CY2027 SAPPHIRE study site conversions — the event most likely to shift the adoption trajectory. The number of sites converting to commercial contracts determines which scenario is tracking.
• July 2026 Q4 FY26 customer receipts — the next quantitative read on commercial momentum. Receipts remaining near the A$46,000 Q3 level confirm stall; a step-change higher signals early traction.
• H1 CY2027 Flow FDA clearance — completes the three-module suite, which would be the only combined anatomy, plaque, and flow offering cleared by the FDA.

Company Description

Artrya develops and sells AI-powered software for analysing coronary CT angiography scans, a growing segment of cardiac imaging. The Salix platform runs three modules. Salix Coronary Anatomy detects and grades arterial blockages. Salix Coronary Plaque characterises plaque composition, distinguishing stable from vulnerable deposits. Salix Coronary Flow, not yet FDA-cleared, will measure fractional flow reserve, a metric indicating whether a blockage actually restricts blood flow. All revenue today comes from three U.S. hospital systems: Tanner Health System, Northeast Georgia Health System, and Cone Health. The company generates approximately A$0.1M in annualised revenue from per-scan fees processed through these sites. Australia and other international markets contribute nothing material at present.

Where the Growth Is

U.S. hospital system adoption accounts for 100% of the revenue base and 100% of the growth thesis. The SAPPHIRE clinical study has enrolled six major U.S. health systems, including Ascension and Mass General Brigham, creating warm commercial leads at top-20 institutions. The bull case requires 150 or more U.S. customers generating over A$100M in revenue by year ten, a trajectory that implies 15 or more new hospital wins annually against a current run rate of zero. CCTA volumes are growing at approximately 6% annually in the U.S., and the US$950 CPT reimbursement code provides validated economics for the per-scan model. The structural demand backdrop is real; the commercial execution question is whether Artrya can capture it ahead of better-resourced competitors.

Competitive Position

Artrya's competitive advantages are real but narrow, with an estimated durability of three to five years before the competitive landscape could erode them. Two FDA 510(k) clearances create regulatory barriers of 18 months or more for new entrants without existing clearances. Integration with PACS and EMR systems (the electronic infrastructure hospitals use to store medical images and manage patient records) generates switching costs once the software is embedded in clinical workflows. The problem is scale. HeartFlow operates at roughly 1,000 installed sites and has spent over a decade building cardiologist relationships and hospital procurement familiarity. Cleerly holds its own plaque clearance and has raised over US$200M in venture capital. Artrya's planned three-module suite would be unique in the market if the Flow module clears the FDA, but product uniqueness without distribution is a laboratory advantage rather than a commercial one. The competitive moat protects the three existing customers but does little to accelerate winning new ones.

Management and Capital Discipline

The current CEO has been in the role for less than a year, and this is their first chief executive appointment. The team delivered both FDA clearances on schedule and raised A$80M without diluting at distressed prices, which represents competent execution on the regulatory and capital markets fronts. Capital preservation has been reasonable: A$76.6M remains on hand and the company has not allocated capital to acquisitions or non-core spending. The problem is commercial execution. After 12 months of active commercial operations, zero organic customers have been added. Scan volumes at the live Tanner site remain undisclosed, which is itself informative: companies with accelerating adoption metrics typically disclose them. Management communications follow a consistent pattern of qualitative optimism ("well positioned," "increasing trend") without quantitative support. That pattern warrants scepticism when assessing any forward guidance the company provides.

Financial Position

The balance sheet is the strongest element of the investment case. Artrya holds A$76.6M in cash and equivalents with zero debt, providing approximately 38 months of runway at the current quarterly burn rate of A$6.8M. The Australian R&D tax incentive refunds approximately A$4-5M annually (43.5% of eligible spend), extending the effective runway beyond what the raw burn rate implies. At current burn rates and without meaningful revenue acceleration, cash depletes by year four, necessitating a capital raise. Management retains the option to rationalise costs from approximately A$25M toward A$15M annually if adoption stalls, which would extend runway by one to two additional years. The balance sheet can absorb several more years of losses, but it cannot fund a decade of sub-scale operations without dilution.